Global histone H4K20 trimethylation predicts cancer-specific survival in patients with muscle-invasive bladder cancer

BJU International

Volumn 108, Issue 8 B, 2011, Pages

  Schneider, Ann Christin ^a   Heukamp, Lukas C ^a   Rogenhofer, Sebastian ^a   Fechner, Guido ^a   Bastian, Patrick J ^b   Von Ruecker, Alexander ^a   Müller, Stefan C ^a   Ellinger, Jörg ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

bladder cancer; epigenetics; H4K20me3; histone; methylation; survival

Indexed keywords

HISTONE H3; HISTONE H3 LYSINE 20; HISTONE H3 LYSINE 4; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLADDER CANCER; BLADDER MUSCLE; CANCER GRADING; CANCER INVASION; CANCER MORTALITY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HISTONE METHYLATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METASTASIS; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE FREE SURVIVAL; TISSUE MICROARRAY;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HISTONES; HUMANS; MALE; METHYLATION; MIDDLE AGED; NEOPLASM INVASIVENESS; PROGNOSIS; SURVIVAL RATE; URINARY BLADDER NEOPLASMS;

EID: 80054046712     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2011.10203.x     Document Type: Article

References (26)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ,. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-49
2. Jeon SH, Jeon SH, Chang SG,. Clinical prognostic factors for radical cystectomy in bladder cancer. Cancer Res Treat 2005; 37: 48-53
3. Millan-Rodriguez F, Chechile-Toniolo G, Salvador-Bayarri J, Palou J, Vicente-Rodriguez J,. Multivariate analysis of the prognostic factors of primary superficial bladder cancer. J Urol 2000; 163: 73-8
4. Enokida H, Nakagawa M,. Epigenetics in bladder cancer. Int J Clin Oncol 2008; 13: 298-307
5. Egger G, Aparicio AM, Escobar SG, Jones PA,. Inhibition of histone deacetylation does not block resilencing of p16 after 5-aza-2′- deoxycytidine treatment. Cancer Res 2007; 67: 346-53 (Pubitemid 46142794)
6. Kouzarides T,. Chromatin modifications and their function. Cell 2007; 128: 693-705 (Pubitemid 46273577)
7. Seligson DB, Horvath S, Shi T, et al,. Global histone modification patterns predict risk of prostate cancer recurrence. Nature 2005; 435: 1262-6 (Pubitemid 40943093)
8. Elsheikh SE, Green AR, Rakha EA, et al,. Global histone modifications in breast cancer correlate with tumor phenotypes, prognostic factors, and patient outcome. Cancer Res 2009; 69: 3802-9
9. Barlesi F, Giaccone G, Gallegos-Ruiz MI, et al,. Global histone modifications predict prognosis of resected non small-cell lung cancer. J Clin Oncol 2007; 25: 4358-64 (Pubitemid 350013840)
10. Ellinger J, Kahl P, Mertens C, et al,. Prognostic relevance of global histone H3 lysine 4 (H3K4) methylation in renal cell carcinoma. Int J Cancer 2010; 127: 2360-6
11. Barbisan F, Mazzucchelli R, Santinelli A, et al,. Immunohistochemical evaluation of global DNA methylation and histone acetylation in papillary urothelial neoplasm of low malignant potential. Int J Immunopathol Pharmacol 2008; 21: 615-23
12. Cheung WL, Albadine R, Chan T, Sharma R, Netto GJ,. Phosphorylated H2AX in noninvasive low grade urothelial carcinoma of the bladder: correlation with tumor recurrence. J Urol 2009; 181: 1387-92
13. Ellinger J, Kahl P, von der Gathen J, et al,. Global levels of histone modifications predict prostate cancer recurrence. Prostate 2010; 70: 61-9
14. Seifert HH, Schmiemann V, Mueller M, et al,. In situ detection of global DNA hypomethylation in exfoliative urine cytology of patients with suspected bladder cancer. Exp Mol Pathol 2007; 82: 292-97 (Pubitemid 46686656)
15. Van Den Broeck A, Brambilla E, Moro-Sibilot D, et al,. Loss of histone H4K20 trimethylation occurs in preneoplasia and influences prognosis of non-small cell lung cancer. Clin Cancer Res 2008; 14: 7237-45
16. Balakrishnan L, Milavetz B,. Decoding the histone H4 lysine 20 methylation mark. Crit Rev Biochem Mol Biol 2010; 45: 440-52
17. Karachentsev D, Sarma K, Reinberg D, Steward R,. PR-Set7-dependent methylation of histone H4 Lys 20 functions in repression of gene expression and is essential for mitosis. Genes Dev 2005; 19: 431-5 (Pubitemid 40256274)
18. Tryndyak VP, Kovalchuk O, Pogribny IP,. Loss of DNA methylation and histone H4 lysine 20 trimethylation in human breast cancer cells is associated with aberrant expression of DNA methyltransferase 1, Suv4-20h2 histone methyltransferase and methyl-binding proteins. Cancer Biol Ther 2006; 5: 65-70 (Pubitemid 43234980)
19. Pogribny IP, Ross SA, Tryndyak VP, Pogribna M, Poirier LA, Karpinets TV,. Histone H3 lysine 9 and H4 lysine 20 trimethylation and the expression of Suv4-20h2 and Suv-39h1 histone methyltransferases in hepatocarcinogenesis induced by methyl deficiency in rats. Carcinogenesis 2006; 27: 1180-6 (Pubitemid 43985433)
20. Shi Y, Lan F, Matson C, Mulligan P, et al,. Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell 2004; 119: 941-53 (Pubitemid 40037608)
21. Fraga MF, Ballestar E, Villar-Garea A, et al,. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet 2005; 37: 391-400
22. Eden A, Gaudet F, Waghmare A, Jaenisch R,. Chromosomal instability and tumors promoted by DNA hypomethylation. Science 2003; 300: 455 (Pubitemid 36444319)
23. Stenzl A, Cowan NC, De Santis M, et al,. The updated EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol 2009; 55: 815-25
24. Kelly WK, Richon VM, O'Connor O, et al,. Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin Cancer Res 2003; 9: 3578-88 (Pubitemid 37169221)
25. Pauer LR, Olivares J, Cunningham C, et al,. Phase I study of oral CI-994 in combination with carboplatin and paclitaxel in the treatment of patients with advanced solid tumors. Cancer Invest 2004; 22: 886-96 (Pubitemid 39665354)
26. Manuyakorn A, Paulus R, Farrell J, et al,. Cellular histone modification patterns predict prognosis and treatment response in resectable pancreatic adenocarcinoma: results from RTOG 9704. J Clin Oncol 2010; 28: 1358-65